Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP

Soranobu Ninomiya, Takeshi Hara, Hisashi Tsurumi, Masato Hoshi, Nobuhiro Kanemura, Naoe Goto, Senji Kasahara, Masahito Shimizu, Hiroyasu Ito, Kuniaki Saito, Yoshinobu Hirose, Tetsuya Yamada, Takeshi Takahashi, Mitsuru Seishima, Tsuyoshi Takami, Hisataka Moriwaki

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Indoleamine 2,3-dioxygenase (IDO) exerts immunomodulatory effects due to enzymatic activities catalyzing the essential amino acid L-tryptophan. IDO activity might play an important role in regulating immune responses exerted by antigen-presenting cells as a potent tool to help escape from assault by the immune system. In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Not only the lymphoma cells themselves but also dendritic cells (DCs) expressed IDO. Positive IDO expression in lymphoma cells was found in 38 cases (32%). Complete remission rates in patients with IDO-positive DLBCL and IDO-negative DLBCL were 55.3% and 79.0% (p=0.008), while 3-year overall survival rates were 49.8% and 78.8%, respectively (p=0.0003). IDO activity might thus play an important role in DLBCL and cells that express IDO appear important for determining outcomes after R-CHOP treatment. IDO might represent a candidate therapeutic target for DLBCL patients who show resistance to chemotherapy.

Original languageEnglish
Pages (from-to)409-416
Number of pages8
JournalAnnals of Hematology
Volume90
Issue number4
DOIs
Publication statusPublished - 04-2011

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP'. Together they form a unique fingerprint.

  • Cite this

    Ninomiya, S., Hara, T., Tsurumi, H., Hoshi, M., Kanemura, N., Goto, N., Kasahara, S., Shimizu, M., Ito, H., Saito, K., Hirose, Y., Yamada, T., Takahashi, T., Seishima, M., Takami, T., & Moriwaki, H. (2011). Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Annals of Hematology, 90(4), 409-416. https://doi.org/10.1007/s00277-010-1093-z